When traditional treatments were no longer effective in relieving his depression, Mathias tried psilocybin therapy outside the current regulatory framework in Belgium. It saved him.
📢 PsychedeliCare will be present at the Piante Maestre Festival in Milan, October 4–5! 🌱✨ At our stand, we’ll be offering 1:1 consultations for those
Max Libert (name changed) is an autistic young man living in Bavaria. Germany recently approved a compassionate use programme under which patients suffering from treatment resistant depression may undergo Psychedelic Assisted Therapy using Psilocybin. And yet, Max is facing years behind bars for self-medicating with mushrooms containing this very compound.
Alexis Arragon (French Team Lead) was invited to present a lecture at the 2025 Congress of Fédération Addiction that took places on the 22-23 of
PsychedeliCare present at the lecture organised by the Amsterdam Psychedelic Research Association on the 10th of April, 2025 On April 10th 2025, APRA will host
On March 20th, Psychedelic Society Maastricht will host the Museum of Consciousness at Maastricht University in The Netherlands. Created and facilitated by esteemed researcher and innovator Carl Hayden Smith, the
On March 4th, the French PsychedeliCare team hosted its launch event, bringing together psychiatrists, journalists, authors, and researchers for an evening to discuss the role of psychedelics
Launch of the European Citizens’ Initiative for mental health in the European Parliament in Brussels Over 100 citizens from 17 EU Member States, 2 European
Interview of PsychedeliCare founder Theo Giubilei in Portuguese magazine “Sabado” with Leonor Riso Sabado: Why did you decide to found this European Citizens’ Initiative? I’m
Today, 14 January 2025, the PsychedeliCare Initiative, the first European Citizens’ Initiative advocating for the integration of psychedelic-assisted therapies into the EU healthcare systems, officially
